Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Corporate Presentation November 2024
Kazia Therapeutics' November 2024 corporate presentation highlights its late-clinical-stage oncology drug development, focusing on high-quality, differentiated clinical-stage assets. Key assets include the brain-penetrant PI3K/mTOR inhibitor Paxalisib, in trials for various brain cancers, and the selective VEGFR3 inhibitor EVT801, targeting lymphangiogenesis in advanced solid tumors. The company's licensing-driven model and potential non-dilutive income opportunities are also discussed.
FDA Committee Casts Negative Vote on Sotagliflozin in Type 1 Diabetes
FDA advisory committee voted 11 to 3 against sotagliflozin's safety-benefit profile for type 1 diabetes and chronic kidney disease, casting doubt on its approval. Lexicon Pharmaceuticals remains hopeful for future approval, citing potential benefits and support from the diabetes community.
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call Transcript
Vir Biotechnology Q3 2024 earnings call highlights missed earnings expectations, strategic licensing agreement with Sanofi, progress in hepatitis delta and B programs, and expansion into oncology with T-cell engager assets.
Bullous Pemphigoid - Executive Insights - Bullous Pemphigoid
Bullous pemphigoid (BP) affects elderly patients, often misdiagnosed, with no approved therapies in the US. Current treatments include off-label corticosteroids and immunomodulators. The BP pipeline includes advanced Phase III therapies like AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent, and Akari Therapeutics’ nomacopan. Unmet needs and market opportunities are significant due to lack of approved therapies and diagnostic biomarkers.
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: St
Vir Biotechnology Inc (VIR) closed a licensing agreement with Sanofi, enhancing oncology and infectious disease pipeline. The company made progress in Hepatitis programs and received fast track designation from the FDA for Hepatitis Delta therapy. Financial position remains robust with $1.19 billion in cash and investments. However, R&D expenses increased to $195 million in Q3 2024, and cash and investments decreased by $245 million. Strategic restructuring includes closing the Portland facility. Q&A highlights include updates on FDA engagement, T cell Engager program, and HDV data benchmarks.
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
Vir Biotechnology Inc reports $195M R&D expenses for Q3 2024, $25.7M SG&A expenses, and $12.7M restructuring charges. Cash and investments stand at $1.19B. Full-year 2024 expense guidance is $660-$680M, with net guidance at $430-$470M. The company closed a licensing agreement with Sanofi, made progress in Hepatitis programs, and received FDA fast track designation for Hepatitis Delta therapy. Financial position remains robust, enabling operations through major milestones.
Stelara May be Effective for Type 1 Diabetes in Adolescents
Stelara (ustekinumab) showed potential in preserving insulin production by reducing Th17.1 cells in a UK phase 2 study, suggesting it could prevent or reduce the need for insulin in type 1 diabetes patients if started early.
Earnings call: Vir Biotechnology advances with Sanofi deal, hepatitis trials
Vir Biotechnology's Q3 2024 earnings call highlights a licensing deal with Sanofi for three T-cell engager programs, progress in hepatitis trials, and a new CFO emphasizing disciplined financial management. The company reported increased R&D expenses and decreased SG&A expenses, ending the quarter with $1.19 billion in cash and equivalents, and updated its full-year 2024 expense guidance.
Lexicon's type 1 diabetes drug voted down by FDA adcomm
FDA advisory committee voted 11 to 3 against Lexicon Pharma's Zynquista approval for type 1 diabetes and CKD, worse than 2019's 8-8 vote. Lexicon secured EU approval but never launched, and FDA approval for heart failure under Inpefa. Some panelists see potential in specific sub-populations, but FDA decision pending.
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Q3 2024 revenues up 11% to $3.72 billion; Dupixent global net sales by Sanofi up 23% to $3.82 billion; U.S. net sales for EYLEA HD and EYLEA up 3% to $1.54 billion; Libtayo global net sales up 24% to $289 million; GAAP diluted EPS up 30% to $11.54; FDA approves Dupixent for COPD and eosinophilic phenotype; positive results for Dupixent in CSU and BP trials.
© Copyright 2025. All Rights Reserved by MedPath